MediciNova Reports the Completion of Patient Enrollment in the P-II Clinical Trial of MN-166 (ibudilast) for Glioblastoma
- The patient enrollment has been completed in the P-II trial evaluating MN-166 in patients with recurrent & newly diagnosed glioblastoma at Dana-Farber Cancer Institute. A dose-escalation phase (part 1) and a fixed-dose phase were included in the P-I/II trial (part 2)
- The dose that will be used in part 2 of the study was established after the part 1 study evaluated the safety & tolerability of an increasing dose of MN-166 when administered in conjunction with temozolomide while part 2 will evaluate the efficacy
- Preliminary results will be presented at the 20th annual world congress of SBMT. MN-166 is a small molecule compound inhibiting PDE4 & inflammatory cytokines, incl. macrophage migration inhibitory factor
Ref: Globenewswire | Image: MediciNova
Related News:- Telix Reports the First Patient Dosing of TLX101 in P-II (IPAX-Linz) Study for the Treatment of Glioblastoma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].